ROAR HMBNCT07589764
Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
At risk: Primary completion moved 1 year 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 1, 2026 to Dec 1, 2026
- Eligibility criteria expanded, about 14 words
- Secondary endpoints: details revised at 2 of 5 entries
- Notable Primary and study completion dates pushed to Oct 1, 2027
- Start date: Jul 1, 2026 to Oct 1, 2026
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
ALS Functional Rating Scale, Revised (ALSFRS-R)
Timeframe: Baseline, month 3, month 9
Speech (Listener Effort)
Timeframe: Baseline, month 3, month 9
Secondary (5)
Neurofilament Light Chain levels (blood)
Neurofilament Light Chain levels (Cerebrospinal fluid (CSF))
Insulin-like growth-factor binding protein 7 (IGFBP7) levels (blood)
Insulin-like growth-factor binding protein 7 (IGFBP7) levels (Cerebrospinal fluid (CSF))
Frequency of ALS reversals
Arms and interventions
β-hydroxy-β-methylbutyrate (HMB) administrationExperimental
Drugs: β-hydroxy-β-methylbutyrate (HMB)
Sites
2 sites in 1 country